1-16 of 16
Ronald Levy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies

Tanaya Shree, Debra Czerwinski, Sarah Haebe, Anuja Sathe, Sue Grimes, Brock Martin, Michael Ozawa, Richard Hoppe, Hanlee Ji, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-2770
Published: 02 January 2025
View article titled, A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies
Open the PDF for A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies in another window
Includes: Supplementary data
Journal Articles

Intratumoral Immunotherapy for Early-stage Solid Tumors

Wan Xing Hong, Sarah Haebe, Andrew S. Lee, C. Benedikt Westphalen, Jeffrey A. Norton, Wen Jiang, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3091–3099.
https://doi.org/10.1158/1078-0432.CCR-19-3642
Published: 01 July 2020
View article titled, Intratumoral Immunotherapy for Early-stage Solid Tumors
Open the PDF for Intratumoral Immunotherapy for Early-stage Solid Tumors in another window
Journal Articles

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2524–2534.
https://doi.org/10.1158/1078-0432.CCR-19-2973
Published: 01 June 2020
View article titled, First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Open the PDF for First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1816–1823.
https://doi.org/10.1158/1078-0432.CCR-17-1922
Published: 12 April 2018
View article titled, Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Open the PDF for Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling

Sarah E. Josefsson, Kanutte Huse, Arne Kolstad, Klaus Beiske, Daniela Pende, Chloé B. Steen, Else Marit Inderberg, Ole Christian Lingjærde, Bjørn Østenstad, Erlend B. Smeland, Ronald Levy, Jonathan M. Irish, June H. Myklebust
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 870–881.
https://doi.org/10.1158/1078-0432.CCR-17-2337
Published: 14 February 2018
View article titled, T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Open the PDF for T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling in another window
Includes: Supplementary data
Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion-Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure-Kunkel, Suba Krishnan, Holbrook Kohrt, Mario Sznol, Ronald Levy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1929–1936.
https://doi.org/10.1158/1078-0432.CCR-16-1272
Published: 13 April 2017
View article titled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open the PDF for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody in another window
Includes: Supplementary data
Journal Articles

Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment

Andrew J. Gentles, Ash A. Alizadeh, Alvaro J. Alencar, Holbrook E. Kohrt, Roch Houot, Matthew J. Goldstein, Yasodha Natkunam, Ranjana H. Advani, Randy D. Gascoyne, Javier Briones, Sylvia K. Plevritis, Izidore S. Lossos, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): PR5.
https://doi.org/10.1158/1078-0432.TCMUSA10-PR5
Published: 02 February 2016
View article titled, Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment
Journal Articles

Abstract IA11: Monoclonal antibodies and in situ vaccination.

Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): IA11.
https://doi.org/10.1158/1557-3265.HEMMAL14-IA11
Published: 19 August 2015
View article titled, Abstract IA11: Monoclonal antibodies and in situ vaccination.
Journal Articles

CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma

Susan J. Knox, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (3): 493–494.
https://doi.org/10.1158/1078-0432.CCR-14-2547
Published: 01 February 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Radioactive Drones for B-cell Lymphoma
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Radioactive Drones for B-cell Lymphoma in another window
Journal Articles

Intratumoral Immunization: A New Paradigm for Cancer Therapy

Aurélien Marabelle, Holbrook Kohrt, Christophe Caux, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1747–1756.
https://doi.org/10.1158/1078-0432.CCR-13-2116
Published: 31 March 2014
View article titled, Intratumoral Immunization: A New Paradigm for Cancer Therapy
Open the PDF for Intratumoral Immunization: A New Paradigm for Cancer Therapy in another window
Journal Articles

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

Aurélien Marabelle, Holbrook Kohrt, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5261–5263.
https://doi.org/10.1158/1078-0432.CCR-13-1923
Published: 01 October 2013
View article titled, Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Open the PDF for Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity in another window
Includes: Supplementary data
Journal Articles

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Emilian Racila, Brian K. Link, Wen-Kai Weng, Thomas E. Witzig, Stephen Ansell, Matthew J. Maurer, Jian Huang, Christopher Dahle, Ahmad Halwani, Ronald Levy, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6697–6703.
https://doi.org/10.1158/1078-0432.CCR-08-0745
Published: 16 October 2008
View article titled, A Polymorphism in the Complement Component <em>C1qA</em> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Open the PDF for A Polymorphism in the Complement Component <em>C1qA</em> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma in another window
Journal Articles

The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy

Thomas A. Davis, Mark S. Kaminski, John P. Leonard, Frank J. Hsu, Mary Wilkinson, Andrew Zelenetz, Richard L. Wahl, Stewart Kroll, Morton Coleman, Michael Goris, Ronald Levy, Susan J. Knox
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 7792–7798.
https://doi.org/10.1158/1078-0432.CCR-04-0756
Published: 07 December 2004
View article titled, The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Open the PDF for The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy in another window
Journal Articles

Detection of CD4 T-Cell Responses to a Tumor Vaccine by Cytokine Flow Cytometry

Holden T. Maecker, Susanne Auffermann-Gretzinger, Laurel E. Nomura, Arcangelo Liso, Debra K. Czerwinski, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 902s–908s.
Published: 01 March 2001
View article titled, Detection of CD4 T-Cell Responses to a Tumor Vaccine by Cytokine Flow Cytometry
Open the PDF for Detection of CD4 T-Cell Responses to a Tumor Vaccine by Cytokine Flow Cytometry in another window
Journal Articles

Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma with Rituximab and Interferon-α-2a

Thomas A. Davis, David G. Maloney, Antonio J. Grillo-López, Christine A. White, Michael E. Williams, George J. Weiner, Sue Dowden, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2644–2652.
Published: 01 July 2000
View article titled, Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma with Rituximab and Interferon-α-2a
Open the PDF for Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma with Rituximab and Interferon-α-2a in another window
Journal Articles

Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression

Thomas A. Davis, Debra K. Czerwinski, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (3): 611–615.
Published: 01 March 1999
View article titled, Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression
Open the PDF for Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression in another window